报道

订阅

MedSci主页 / 所有栏目 / 报道

卡妥索单抗治疗晚期胃癌伴腹膜转移临床研究成果入选2022ASCO年会

2022-05-30 网络 网络

美国临床肿瘤学会凌腾医药卡妥索单抗治疗晚期胃癌伴腹膜转移
关注

凌腾医药是一家专注于T细胞衔接抗体开发的临床阶段生物制药公司。该公司今日宣布，美国临床肿瘤学会（American Society of Clinical Oncology, ASCO）已接收卡妥索单抗

凌腾医药是一家专注于T细胞衔接抗体开发的临床阶段生物制药公司。该公司今日宣布，美国临床肿瘤学会（American Society of Clinical Oncology, ASCO）已接收卡妥索单抗治疗晚期胃癌伴腹膜转移的Ⅲ期临床试验第一阶段研究成果作为摘要发布。

摘要编号：e16102
摘要标题：Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.

此次公布了卡妥索单抗治疗晚期胃癌伴腹膜转移国际多中心Ⅲ期临床试验第一阶段（Stage 1）cohort A的临床数据（clinicaltrials.gov: NCT04222114）。全球每年胃癌新发病例超过100万例【1】，50%以上的晚期胃癌患者在根治性切除术后出现腹膜转移，且部分合并有恶性腹水，严重影响生活质量【2】。由于目前缺乏对晚期胃癌伴腹膜转移的针对性疗法，这类患者在三线全身治疗失败后的预期生存期仅为2.3-2.4个月。cohort A入组的9名患者（1/3的患者已接受三线治疗）接受卡妥索单抗治疗后，中位总生存期（median overall survival）为3.4个月，伴有较明显的腹水消退。卡妥索单抗已初步展现在该适应症上的治疗潜力。

Reference

1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. 季加孚,沈琳,徐惠绵,徐瑞华,朱正纲,程向东,刘云鹏,李子禹,陕飞,孙宇,唐磊,周军,张小田.胃癌腹膜转移防治中国专家共识[J].中华胃肠外科杂志,2017,20(05):481-490.

关于卡妥索单抗

卡妥索单抗于2009年获得了欧洲药品管理局批准用于治疗EpCAM阳性恶性肿瘤引起的恶性腹水，是全球第一个上市的T细胞衔接双特异性抗体药物。卡妥索单抗结合肿瘤相关性抗原EpCAM和T细胞的CD3受体，同时通过与FcɣR招募免疫附属细胞，协同T细胞杀伤肿瘤细胞并产生潜在的肿瘤疫苗作用。目前，卡妥索单抗胃癌适应症正开展国际多中心Ⅲ期临床试验（NCT04222114），膀胱癌适应症正开展Ⅰ/Ⅱ期临床试验（NCT04799847）。

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2023-04-10 fanweitanzhen

    #临床研究成果#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-09-25 xiongliangxl

    #研究成果#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-08-14 quxin068

    #ASC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-06-01 drj2003

    #晚期胃癌#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-06-01 新生儿张玉军

    #腹膜转移#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
    2022-06-01 xuyong530

    #腹膜#

    0

相关资讯

2019年美国临床肿瘤学会（ASCO）全新汇总

2019美国临床肿瘤学会（ASCO）最新汇总

多项Watson中国本土应用研究成果亮相ASCO

5月31日-6月4日，2019年美国临床肿瘤学会（以下简称“ASCO”）年会在芝加哥召开，中国研究者有9篇有关Watson for Oncology（以下简称“WfO”）的研究报告入选ASCO，全面解读WfO在中国肿瘤临床应用中的最新数据、成果和进展。年会期间，北京大学国际医院副院长、肿瘤内科主任梁军表示：“今年ASCO大会上，以WfO为代表的人工智能临床决策支持系统是目前最受瞩目的研究和应用领域

Agendia的MammaPrint®检测在NSABP B-42试验中率先展示出预测延长内分泌治疗所带来收益的能力

• MammaPrint是唯一能预测接受延长内分泌治疗的患者的DFS和BCFI事件分别显著减少36%和52%的检测 • 用于内分泌处治决策的MammaPrint检测最早将于2021年第三季度在美国及世

PCOS 2015：ASCO、AAHPM联合发布肿瘤姑息治疗指导声明

美国临床肿瘤学会（ASCO">ASCO）的肿瘤姑息治疗论坛（Palliative Care in Oncology Symposium 2015，PCOS 2015）将于10月9-10日于美国波士顿召开。PCOS 2015新闻发布会在美东时间10月5日下午12时举行。 在2015年肿瘤姑息治疗论坛（PCOS 2015）上，美国临床肿瘤学会（ASCO）和美国宁养与姑息医学会（AAHPM）将联

Guardian：口腔性行为与喉癌有关？

Michael Douglas: "because, without wanting to get too specific, this particular cancer is caused by HPV, which actually comes about from cunnilingus." 多年来，人们认为吸烟和饮酒是导致喉癌的主要危险因素。但是，周一，英国报纸《卫报》（Th

拓展阅读

读书报告 | 纳武利尤单抗联合化疗或联合伊匹木单抗治疗食管癌、食管-胃结合部癌和胃癌的生物标志物分析

分析胃和食管腺癌基因背景有助于选择恰当治疗方案，改善预后。

【综述】｜工智能在胃癌诊疗和患者预后预测中的应用现状及未来展望

本文将重点综述DL在胃癌诊断、疗效评估和预后预测中的应用现状及未来发展方向。

论文解读｜严俊/黄锐敏/庞涛联合团队揭示弥漫型胃癌中GXYLT2抑制PP2A而活化β-catenin

该研究通过构建新型分子分型系统，成功地筛选出与胃癌患者的肿瘤分期和不良生存结局呈正相关的糖苷木糖基转移酶2基因GXYLT2。

王湘教授谈胃癌治疗“新蓝海”：免疫治疗+生物标志物检测，开启精准时代

【医悦汇】有幸邀请到北京协和医院王湘教授做客对话大咖栏目，聚焦胃癌免疫治疗的最新进展与临床应用现状，深入探讨生物标志物在精准治疗中的关键作用，以及未来可能改变治疗格局的新方向。

JHO：中国胃癌和胃食管交界处癌诊断与治疗的现状

该研究生动反映了中国胃癌诊断和治疗实践的最新发展，为优化策略制定具有重要参考价值。

Gut | DNA甲基化新标志预测胃癌风险：一项多中心前瞻性研究揭示高危人群筛查新策略

本研究创新性地在临床高危人群中验证了DNA甲基化标志物RIMS1作为预测胃癌风险的有效工具。

关于公开征求《晚期胃癌新药临床试验设计指导原则（征求意见稿）》意见的通知

国家药品监督管理局药品审评中心（CDE） · 2024-06-17

腹腔镜手术在晚期胃癌中应用争议与共识

暂未更新 · 2023-09-01

2023 NICE 技术鉴定指导意见：纳武单抗联合铂类和氟嘧啶类化疗治疗未经治疗的HER2阴性晚期胃癌、胃食管交界处癌或食管腺癌[TA857]

英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence) · 2023-01-11